Beta Bionics (NASDAQ:BBNX) Insider Sells $53,239.42 in Stock

Posted by Geri Gentry on Jun 6th, 2026

Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Steven Jon Russell sold 4,222 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $53,239.42. Following the completion of the transaction, the insider owned 173,849 shares of the company’s stock, valued at approximately $2,192,235.89. This trade represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Stock Performance

Shares of Beta Bionics stock opened at $13.89 on Friday. The firm has a 50-day simple moving average of $10.93 and a two-hundred day simple moving average of $17.19. The company has a market cap of $618.94 million, a P/E ratio of -9.20 and a beta of 3.40. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last issued its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The business had revenue of $27.63 million during the quarter. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. Equities research analysts forecast that Beta Bionics, Inc. will post -2.19 EPS for the current year.

Institutional Trading of Beta Bionics

Large investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC purchased a new stake in Beta Bionics during the 3rd quarter valued at about $4,423,000. JPMorgan Chase & Co. grew its stake in Beta Bionics by 3,238.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 205,955 shares of the company’s stock valued at $4,092,000 after acquiring an additional 199,785 shares in the last quarter. Pura Vida Investments LLC grew its stake in Beta Bionics by 11,150.0% during the 3rd quarter. Pura Vida Investments LLC now owns 281,250 shares of the company’s stock valued at $5,588,000 after acquiring an additional 278,750 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Beta Bionics during the 4th quarter valued at about $4,579,000. Finally, Farallon Capital Management LLC grew its stake in Beta Bionics by 2.6% during the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock valued at $85,718,000 after acquiring an additional 110,000 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a research note on Monday, February 9th. The Goldman Sachs Group cut their target price on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Truist Financial cut their target price on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Leerink Partners cut their target price on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. Finally, Wall Street Zen cut shares of Beta Bionics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus price target of $19.70.

Read Our Latest Analysis on Beta Bionics

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.